Report Detail
Global (United States, European Union and China) Renal Cell Cacinoma Drugs Market Research Report 2019-2025
- RnM3348693 |
- 23 April, 2019 |
- Global |
- 126 Pages |
- QYResearch |
- Pharma & Healthcare
In 2019, the market size of Renal Cell Cacinoma Drugs is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Renal Cell Cacinoma Drugs.
This report studies the global market size of Renal Cell Cacinoma Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Renal Cell Cacinoma Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Merck & Co., Inc.
Exelixis Inc
Argus Therapeutics, Inc.
Bristol-Myers Squibb
Genentech
Immatics Biotechnologies
AVEO Oncology
Eisai
Acceleron
Rexahn Pharmaceuticals
Bionomics
Cerulean Pharma Inc
Celldex Therapeutics
TVAX Biomedical
TRACON Pharmaceuticals
Market Segment by Product Type
Sutent(Sunitinib)
Nexavar(Sorafenib)
Votrient(Pazopanib)
Avastin(Bevacizumab)
Afinitor(Everolimus)
Inlyta(Axitinib)
Torisel(Temsirolimus)
Proleukin(Aldesleukin)
Market Segment by Application
Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
Multilocular Cystic Clear Cell Renal Cell Carcinoma
Tubulocystic Renal Cell Carcinoma
Thyroid-Like Follicular Renal Cell Carcinoma
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Renal Cell Cacinoma Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Renal Cell Cacinoma Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Renal Cell Cacinoma Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Renal Cell Cacinoma Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Sutent(Sunitinib)
- 1.3.3 Nexavar(Sorafenib)
- 1.3.4 Votrient(Pazopanib)
- 1.3.5 Avastin(Bevacizumab)
- 1.3.6 Afinitor(Everolimus)
- 1.3.7 Inlyta(Axitinib)
- 1.3.8 Torisel(Temsirolimus)
- 1.3.9 Proleukin(Aldesleukin)
- 1.4 Market Segment by Application
- 1.4.1 Global Renal Cell Cacinoma Drugs Market Share by Application (2019-2025)
- 1.4.2 Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
- 1.4.3 Multilocular Cystic Clear Cell Renal Cell Carcinoma
- 1.4.4 Tubulocystic Renal Cell Carcinoma
- 1.4.5 Thyroid-Like Follicular Renal Cell Carcinoma
- 1.4.6 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Renal Cell Cacinoma Drugs Market Size
- 2.1.1 Global Renal Cell Cacinoma Drugs Revenue 2014-2025
- 2.1.2 Global Renal Cell Cacinoma Drugs Sales 2014-2025
- 2.2 Renal Cell Cacinoma Drugs Growth Rate by Regions
- 2.2.1 Global Renal Cell Cacinoma Drugs Sales by Regions 2014-2019
- 2.2.2 Global Renal Cell Cacinoma Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Renal Cell Cacinoma Drugs Sales by Manufacturers
- 3.1.1 Renal Cell Cacinoma Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Renal Cell Cacinoma Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Renal Cell Cacinoma Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Renal Cell Cacinoma Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Renal Cell Cacinoma Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Renal Cell Cacinoma Drugs Price by Manufacturers
- 3.4 Key Manufacturers Renal Cell Cacinoma Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Renal Cell Cacinoma Drugs Market
- 3.6 Key Manufacturers Renal Cell Cacinoma Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Sutent(Sunitinib) Sales and Revenue (2014-2019)
- 4.1.2 Nexavar(Sorafenib) Sales and Revenue (2014-2019)
- 4.1.3 Votrient(Pazopanib) Sales and Revenue (2014-2019)
- 4.1.4 Avastin(Bevacizumab) Sales and Revenue (2014-2019)
- 4.1.5 Afinitor(Everolimus) Sales and Revenue (2014-2019)
- 4.1.6 Inlyta(Axitinib) Sales and Revenue (2014-2019)
- 4.1.7 Torisel(Temsirolimus) Sales and Revenue (2014-2019)
- 4.1.8 Proleukin(Aldesleukin) Sales and Revenue (2014-2019)
- 4.2 Global Renal Cell Cacinoma Drugs Sales Market Share by Type
- 4.3 Global Renal Cell Cacinoma Drugs Revenue Market Share by Type
- 4.4 Renal Cell Cacinoma Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Renal Cell Cacinoma Drugs Sales by Application
6 United States
- 6.1 United States Renal Cell Cacinoma Drugs Breakdown Data by Company
- 6.2 United States Renal Cell Cacinoma Drugs Breakdown Data by Type
- 6.3 United States Renal Cell Cacinoma Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Renal Cell Cacinoma Drugs Breakdown Data by Company
- 7.2 European Union Renal Cell Cacinoma Drugs Breakdown Data by Type
- 7.3 European Union Renal Cell Cacinoma Drugs Breakdown Data by Application
8 China
- 8.1 China Renal Cell Cacinoma Drugs Breakdown Data by Company
- 8.2 China Renal Cell Cacinoma Drugs Breakdown Data by Type
- 8.3 China Renal Cell Cacinoma Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Renal Cell Cacinoma Drugs Breakdown Data by Company
- 9.2 Rest of World Renal Cell Cacinoma Drugs Breakdown Data by Type
- 9.3 Rest of World Renal Cell Cacinoma Drugs Breakdown Data by Application
- 9.4 Rest of World Renal Cell Cacinoma Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Renal Cell Cacinoma Drugs Sales by Countries
- 9.4.2 Rest of World Renal Cell Cacinoma Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Merck & Co., Inc.
- 10.1.1 Merck & Co., Inc. Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Renal Cell Cacinoma Drugs
- 10.1.4 Renal Cell Cacinoma Drugs Product Introduction
- 10.1.5 Merck & Co., Inc. Recent Development
- 10.2 Exelixis Inc
- 10.2.1 Exelixis Inc Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Renal Cell Cacinoma Drugs
- 10.2.4 Renal Cell Cacinoma Drugs Product Introduction
- 10.2.5 Exelixis Inc Recent Development
- 10.3 Argus Therapeutics, Inc.
- 10.3.1 Argus Therapeutics, Inc. Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Renal Cell Cacinoma Drugs
- 10.3.4 Renal Cell Cacinoma Drugs Product Introduction
- 10.3.5 Argus Therapeutics, Inc. Recent Development
- 10.4 Bristol-Myers Squibb
- 10.4.1 Bristol-Myers Squibb Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Renal Cell Cacinoma Drugs
- 10.4.4 Renal Cell Cacinoma Drugs Product Introduction
- 10.4.5 Bristol-Myers Squibb Recent Development
- 10.5 Genentech
- 10.5.1 Genentech Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Renal Cell Cacinoma Drugs
- 10.5.4 Renal Cell Cacinoma Drugs Product Introduction
- 10.5.5 Genentech Recent Development
- 10.6 Immatics Biotechnologies
- 10.6.1 Immatics Biotechnologies Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Renal Cell Cacinoma Drugs
- 10.6.4 Renal Cell Cacinoma Drugs Product Introduction
- 10.6.5 Immatics Biotechnologies Recent Development
- 10.7 AVEO Oncology
- 10.7.1 AVEO Oncology Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Renal Cell Cacinoma Drugs
- 10.7.4 Renal Cell Cacinoma Drugs Product Introduction
- 10.7.5 AVEO Oncology Recent Development
- 10.8 Eisai
- 10.8.1 Eisai Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Renal Cell Cacinoma Drugs
- 10.8.4 Renal Cell Cacinoma Drugs Product Introduction
- 10.8.5 Eisai Recent Development
- 10.9 Acceleron
- 10.9.1 Acceleron Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Renal Cell Cacinoma Drugs
- 10.9.4 Renal Cell Cacinoma Drugs Product Introduction
- 10.9.5 Acceleron Recent Development
- 10.10 Rexahn Pharmaceuticals
- 10.10.1 Rexahn Pharmaceuticals Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Renal Cell Cacinoma Drugs
- 10.10.4 Renal Cell Cacinoma Drugs Product Introduction
- 10.10.5 Rexahn Pharmaceuticals Recent Development
- 10.11 Bionomics
- 10.12 Cerulean Pharma Inc
- 10.13 Celldex Therapeutics
- 10.14 TVAX Biomedical
- 10.15 TRACON Pharmaceuticals
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Renal Cell Cacinoma Drugs Sales Channels
- 11.2.2 Renal Cell Cacinoma Drugs Distributors
- 11.3 Renal Cell Cacinoma Drugs Customers
12 Market Forecast
- 12.1 Global Renal Cell Cacinoma Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Renal Cell Cacinoma Drugs Sales Forecast by Type
- 12.3 Global Renal Cell Cacinoma Drugs Sales Forecast by Application
- 12.4 Renal Cell Cacinoma Drugs Forecast by Regions
- 12.4.1 Global Renal Cell Cacinoma Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Renal Cell Cacinoma Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Renal Cell Cacinoma Drugs. Industry analysis & Market Report on Renal Cell Cacinoma Drugs is a syndicated market report, published as Global (United States, European Union and China) Renal Cell Cacinoma Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Renal Cell Cacinoma Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
